Generated by All in One SEO v4.9.1.1, this is an llms.txt file, used by LLMs to index the site.

# IMMIX BIOPHARMA INC

Clinical CAR-T Trailblazer

## Sitemaps

- [XML Sitemap](https://immixbio.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Immix Biopharma to Participate in the Jefferies Global Healthcare Conference](https://immixbio.com/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference/) - LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will
- [Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones](https://immixbio.com/immix-biopharma-announces-enrollment-completion-of-bla-enabling-relapsed-refractory-al-amyloidosis-trial-nexicart-2-and-upcoming-milestones/) - - Full enrollment of BLA-enabling trial complete, per prior guidance -- Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch -- Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission - LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company",
- [Immix Biopharma to Participate in Upcoming Investor Conferences](https://immixbio.com/immix-biopharma-to-participate-in-upcoming-investor-conferences/) - LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences: Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in
- [Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201](https://immixbio.com/immix-biopharma-receives-u-s-fda-breakthrough-therapy-designation-for-nxc-201/) - - Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting - - Final data expected this year followed by planned BLA submission - LOS ANGELES, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We"
- [Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants](https://immixbio.com/immix-biopharma-announces-closing-of-upsized-100-million-underwritten-offering-of-common-stock-and-pre-funded-warrants/) - - Financing includes leading U.S. biotechnology institutional investors and mutual funds - LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common
- [Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants](https://immixbio.com/immix-biopharma-announces-pricing-of-upsized-100-million-underwritten-offering-of-common-stock-and-pre-funded-warrants/) - LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain
- [At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis](https://immixbio.com/at-ash-2025-oral-presentation-immix-biopharma-reports-positive-phase-2-nxc-201-results-advancing-toward-bla-submission-as-a-potentially-first-and-best-in-class-therapy-for-relapsed-refractory-al-am/) - - NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee - - In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% - - NEXICART-2 final readout and BLA submission planned in 2026
- [Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch](https://immixbio.com/immix-biopharma-appoints-chief-commercial-officer-to-drive-nxc-201-launch/) - - Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix's U.S. launch and commercial buildout for NXC-201 in relapsed/refractory AL Amyloidosis, a serious, rare, blood disease with no currently
- [Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025](https://immixbio.com/immix-biopharmas-nxc-201-nexicart-2-clinical-trial-results-selected-for-oral-presentation-at-ash-2025/) - - Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected
- [Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference](https://immixbio.com/immix-biopharma-to-present-at-the-guggenheim-2nd-annual-healthcare-innovation-conference/) - LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA. Management will
- [Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting](https://immixbio.com/immix-biopharma-to-present-abstract-at-the-upcoming-ash-2025-annual-meeting/) - Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in
- [Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference](https://immixbio.com/immix-biopharma-to-present-at-the-37th-annual-piper-sandler-healthcare-conference/) - Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on
- [Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2](https://immixbio.com/immix-biopharma-announces-50-enrollment-milestone-surpassed-in-its-ongoing-relapsed-refractory-al-amyloidosis-clinical-trial-nexicart-2/) - - On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis - Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced
- [Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors](https://immixbio.com/nancy-t-chang-proven-biotechnology-leader-joins-immix-biopharma-board-of-directors/) - - Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far - Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("Company", "We" or "Us"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T.
- [Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang](https://immixbio.com/immix-biopharma-announces-strategic-investment-by-houston-based-goose-capital-led-by-founding-member-dr-nancy-t-chang/) - LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose
- [Immix Biopharma to Present at the Stifel 2025 Healthcare Conference](https://immixbio.com/immix-biopharma-to-present-at-the-stifel-2025-healthcare-conference/) - Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference being held on November 11-13,
- [Immix Biopharma Announces Other Serious Diseases Strategy](https://immixbio.com/immix-biopharma-announces-other-serious-diseases-strategy/) - - Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) - - Company plans to partner-out Other Serious Disease programs - - On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis - LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.
- [Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion](https://immixbio.com/immix-biopharma-announces-class-leading-safety-profile-allowing-potential-future-indication-expansion/) - - Absence of neurotoxicity of any grade in low-volume disease to-date - - On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis - - Potential future indication expansion planned - LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or
- [Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis](https://immixbio.com/immix-biopharma-announces-accelerated-nexicart-2-clinical-trial-progress-in-relapsed-refractory-al-amyloidosis/) - - National Footprint of NEXICART-2 Trial Sites Expanded - - On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication - - NEXICART-2 interim results were presented at ASCO 2025 - LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"),
- [Immix Biopharma Attends FDA CEO Forum in Washington DC](https://immixbio.com/immix-biopharma-attends-fda-ceo-forum-in-washington-dc/) - - Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. - LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that
- [Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis](https://immixbio.com/immix-biopharma-announces-primary-endpoint-met-in-positive-nxc-201-interim-results-presented-at-asco-enabling-path-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis/) - Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. - NXC-201 met primary endpoint with a complete response (CR) rate of 70% (7/10 patients) - - No relapses recorded to-date; no safety signals identified - - Immix plans Biologics License Application (BLA)
- [Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2](https://immixbio.com/immix-biopharma-further-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial-nexicart-2/) - - Patient enrollment exceeding expectations - - 14 U.S. sites actively enrolling; 10 U.S. sites added since last update - - Anticipate completing NEXICART-2 clinical trial ahead of schedule - LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell
- [Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis](https://immixbio.com/immix-biopharma-announces-positive-results-for-nxc-201-at-asco-oral-presentation-enabling-pathway-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis/) - Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. - NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) - - No relapses recorded to-date; no safety signals identified - - Updated results with a later data cutoff,
- [Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis](https://immixbio.com/immix-biopharma-to-host-kol-event-to-discuss-nxc-201-clinical-data-presented-at-asco-2025-in-relapsed-refractory-al-amyloidosis/) - - Virtual KOL Event Tuesday, June 3, 2025 3:00pm ET - - Attend the event here: https://lifescievents.com/event/immix-asco - LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will
- [Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025](https://immixbio.com/immix-biopharmas-nxc-201-nexicart-2-clinical-trial-data-selected-for-oral-presentation-at-asco-2025/) - - Oral presentation Tuesday, June 3, 2025 in Chicago - LOS ANGELES, April 23, 2025 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in
- [Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis](https://immixbio.com/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-nxc-201-sterically-optimized-car-t-for-relapsed-refractory-al-amyloidosis/) - FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation potentially streamlines the path to market approval by allowing frequent interactions with FDA and routes to FDA Accelerated Approval and Priority ReviewEnrollment in NEXICART-2 study accelerating; next update planned for H1 2025 LOS ANGELES,CA, Feb.
- [Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T](https://immixbio.com/immix-biopharma-accelerates-enrollment-in-u-s-al-amyloidosis-trial-of-nxc-201-car-t/) - Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in development for AL AmyloidosisNext program update Q1 2025 AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S. LOS ANGELES,
- [Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis](https://immixbio.com/immix-biopharma-announces-positive-u-s-clinical-data-from-first-four-patients-in-nexicart-2-u-s-trial-of-sterically-optimized-car-t-nxc-201-in-relapsed-refractory-light-chain-al-amyloidosis/) - All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow MRD negative (10-6); all patients remain in response as of the data cutoff of Nov 14, 2024Bone marrow MRD negativity predicts future CR;
- [Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis](https://immixbio.com/journal-of-clinical-oncology-publishes-nxc-201-positive-clinical-results-in-relapsed-refractory-al-amyloidosis/) - Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients LOS ANGELES, Dec. 16, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company
- [Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024](https://immixbio.com/immix-biopharma-announces-75-complete-response-rate-n16-31-5-months-best-response-duration-ongoing-for-car-t-nxc-201-in-relapsed-refractory-al-amyloidosis-patients-at-ash-2024/) - 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December 9, 2024Best responder duration of response was 31.5 months with complete response ongoing as of December 9, 2024Conference call to discuss results Tuesday, December
- [Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media](https://immixbio.com/immix-biopharma-to-host-conference-call-for-investors-analysts-and-members-of-the-media/) - - Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management's formal remarks, there will be a question-and-answer session. - Conference Call to be held Tuesday, December 10, 2024 at 4:30 p.m. Eastern Time - Interested parties can attend the conference call via Zoom using the
- [Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients](https://immixbio.com/immix-biopharma-presents-positive-nxc-201-clinical-data-at-66th-american-society-of-hematology-ash-annual-meeting-in-16-relapsed-refractory-al-amyloidosis-patients/) - 75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for
- [Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2](https://immixbio.com/immix-biopharma-advances-car-t-nxc-201-to-expansion-cohort-dose-level-in-u-s-al-amyloidosis-trial-nexicart-2/) - Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studiesLead site Memorial Sloan Kettering Cancer Center (MSKCC); 4 disclosed clinical sites so farNXC-201 is the only one-time CAR-T treatment option
- [Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board](https://immixbio.com/immix-biopharma-announces-dr-raymond-comenzo-internationally-recognized-al-amyloidosis-expert-director-of-the-myeloma-and-amyloid-program-at-tufts-medical-center-joins-scientific-advisory-board/) - Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials
- [Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2](https://immixbio.com/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial-nexicart-2-2/) - New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Data from ex-U.S. clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, CA, Aug. 28, 2024 -- Immix Biopharma, Inc. ("ImmixBio",
- [ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site](https://immixbio.com/immixbio-approves-4-additional-clinical-trial-sites-for-imx-110-clinical-trials-complementing-existing-soft-tissue-sarcoma-lead-site/) - California Soft Tissue Sarcoma Site to lead expanded clinical site consortiumHistorically, high-enrolling lead site has enrolled 2-3 patients per monthClinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 A photo accompanying this announcement
- [ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials](https://immixbio.com/immixbio-completes-gmp-manufacturing-of-scaled-up-batch-of-imx-110-for-clinical-trials/) - Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma ("STS")2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92 LOS ANGELES, Sept. 07, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX)
- [ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study](https://immixbio.com/immixbio-imx-110-demonstrated-improved-survival-over-u-s-food-and-drug-administration-approved-drug-trabectedin-sold-as-yondelis-by-janssen-a-johnson-johnson-company-in-connective-tis/) - One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugsIMX-110 is in clinical development for STS, a $3 billion market expected
- [Immix Biopharma Announces Share Repurchase Program](https://immixbio.com/immix-biopharma-announces-share-repurchase-program/) - LOS ANGELES, May 09, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's common stock. The Company may
- [ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022](https://immixbio.com/immixbio-management-discusses-key-milestones-drug-development-timelines-and-the-immx-advantage-at-immx-milestone-day-event-held-on-april-5-2022/) - The IMMX Milestone Day Event is viewable at immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities presented by current market volatilityImmixBio plans to commence 2 clinical trials in 2022 LOS ANGELES, April 05, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and
- [Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022](https://immixbio.com/immix-biopharma-inc-announces-immx-milestone-day-to-be-held-on-april-5-2022/) - Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29ada955-df7a-4722-968a-3a3e0fd0d34d LOS ANGELES, March 07, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio",
- [ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease](https://immixbio.com/immixbio-initiates-gmp-manufacturing-of-imx-120-a-biologic-for-inflammatory-bowel-disease/) - IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cellsImmixBio anticipates filing an IND for IMX-120 in 2023The inflammatory bowel disease market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019 A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4733027e-ec5e-4598-9b6e-d5a9c4031c56 LOS ANGELES, Feb. 22,
- [ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022](https://immixbio.com/immixbio-management-answers-top-voted-investor-questions-at-immx-investors-day-february-1-2022/) - LOS ANGELES, Feb. 01, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET. ImmixBio
- [ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data](https://immixbio.com/immixbio-initiates-imx-110-gmp-manufacturing-scale-up-potentially-accelerating-clinical-trial-data/) - Manufactured IMX-110 to be utilized in both clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma ("STS")2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors An image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d. LOS ANGELES, Jan. 31, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or
- [IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale](https://immixbio.com/imx-110-anti-pd-1-combination-produced-extended-median-survival-in-genetic-pancreatic-cancer-mouse-model-bolstering-planned-2022-imx-110-combination-clinical-trial-rationale/) - IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune systemHistorically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and 2 immunotherapies in the same genetic pancreatic cancer mouse model according to
- [ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles](https://immixbio.com/immixbio-announces-positive-imx-110-phase-1b-2a-interim-clinical-trial-safety-data-demonstrating-100-completion-of-planned-treatment-cycles/) - 100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trialIMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 billion market expected to grow to $6.5 billion by 2030 A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b83a7ede-262b-4777-a2f9-beb13ee761bc LOS ANGELES,
- [ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study](https://immixbio.com/immixbio-imx-110-produced-50-positive-response-rate-in-first-line-therapy-resistant-cancer-surpassing-the-standard-of-care-in-mice-study/) - IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice studyIMX-110 response rate surpassed standard of care doxorubicin's response rate of 0% after 1 cycle of treatment in the same studyIMX-110 is in clinical development for STS, a $3 billion market expected
- [Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders](https://immixbio.com/immix-biopharma-announces-immx-investors-day-to-be-held-on-february-1-2022-qa-platform-for-all-shareholders/) - Los Angeles, CA, Jan. 06, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the IMMX Investors Day Event, to be held on February 1, 2022, and the launch of an online Q&A platform for all shareholders to
- [U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children](https://immixbio.com/u-s-food-and-drug-administration-approves-immix-biopharma-rare-pediatric-disease-designation-for-imx-110-as-a-treatment-for-life-threatening-pediatric-cancer-in-children/) - Rare Pediatric Disease Designation ("RPDD") qualifies Immix Biopharma to receive fast track review, and a priority review voucher ("PRV") at the time of marketing approval of IMX-110.PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA.While their future value is uncertain, PRVs are transferable to
- [Immix Biopharma, Inc. Announces Closing of Initial Public Offering](https://immixbio.com/immix-biopharma-inc-announces-closing-of-initial-public-offering/) - LOS ANGELES, CA, Dec. 20, 2021 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for
- [Immix Biopharma, Inc. Announces Pricing of Initial Public Offering](https://immixbio.com/immix-biopharma-inc-announces-pricing-of-initial-public-offering/) - LOS ANGELES, Dec. 15, 2021 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for gross
- [Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors](https://immixbio.com/immix-doses-first-patient-in-usa-in-its-phase-1b-2a-trial-in-patients-with-advanced-solid-tumors/) - LOS ANGELES, Feb. 4, 2020 -- Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors. To-date, the trial has accrued patients across tumor types. The expansion of the study to the US builds upon
- [ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14](https://immixbio.com/immixbio-to-discuss-recent-positive-nxc-201-clinical-data-in-al-amyloidosis-and-multiple-myeloma-at-the-35th-annual-roth-conference-on-march-14/) - LOS ANGELES, March 06, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc. ("Nexcella"), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that
- [Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission](https://immixbio.com/nexcella-announces-50-patients-already-treated-with-car-t-nxc-201-estimates-100-patient-total-enrollment-for-u-s-food-and-drug-administration-approval-bla-submission/) - Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis Nexcella on track to present 50-patient cohort multiple myeloma data later this year at a premier scientific forum Los Angeles, Feb. 27, 2023 -- Nexcella, Inc. ("Nexcella", "Company"),
- [Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.](https://immixbio.com/immix-biopharma-subsidiary-nexcella-enters-into-u-s-gmp-manufacturing-agreement-to-expand-ongoing-nxc-201-phase-1b-2-clinical-trial-to-the-u-s/) - Nexcella, Inc. initiates process of bringing NXC-201 to the United States by entering into an agreement with a well-known GMP cell therapy manufacturer that will supply Phase 1b/2 NXC-201 clinical trial materialNXC-201 is in development for the treatment of patients with relapsed or refractory multiple myeloma and light chain (AL) amyloidosis Nexcella believes recently reported
- [Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting](https://immixbio.com/immix-biopharma-subsidiary-nexcella-inc-presents-42-patient-interim-data-with-90-overall-response-rate-in-relapsed-or-refractory-multiple-myeloma-at-nxc-201-therapeutic-dose-from-its-phase-1-expans/) - The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the data cutoff of October 23, 202290% overall response rate (ORR) was observed in 29 multiple myeloma patients receiving the therapeutic
- [Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer](https://immixbio.com/immix-biopharma-announces-dosing-of-first-2-patients-in-its-imx-110-beigene-novartis-anti-pd-1-tislelizumab-phase-1b-2a-combination-clinical-trial-in-patients-with-advanced-cancer/) - IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically "cold" tumors "hot"Initial data anticipated in 1H 2023 LOS ANGELES, Feb. 07, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced dosing
- [Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial](https://immixbio.com/immix-biopharma-doses-additional-patients-in-ongoing-phase-1b-2a-imx-110-monotherapy-clinical-trial/) - In January 2023, the 17th new patient was dosed with IMX-110 to datePositive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, Jan. 13,
- [Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached](https://immixbio.com/immix-biopharma-subsidiary-nexcella-inc-announces-additional-positive-nxc-201-clinical-data-demonstrating-100-complete-responses-in-relapsed-refractory-al-amyloidosis-patients-duration-of-response/) - NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022 in Clinical Cancer Research demonstrated 100% complete response rate; 100% organ response rate; Duration of Response Not Yet Reached at a median follow-up of 5.2 months, resulting in a mean 65% reduction (2,656pg/mL) in NT-proBNP
- [Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting](https://immixbio.com/nexcella-inc-a-subsidiary-of-immix-biopharma-announces-poster-presentation-at-the-european-society-for-blood-and-marrow-transplantation-and-european-hematology-association-5th-annual-european-car/) - Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023LOS ANGELES, CA, Dec. 28, 2022 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected to
- [Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial](https://immixbio.com/immix-biopharma-announces-16th-patient-dosing-in-ongoing-phase-1b-2a-imx-110-monotherapy-clinical-trial/) - 16th patient dosed with IMX-110 to dateThis is the second patient dosed with IMX-110 in December 2022Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, CA, Dec. 20, 2022 -- Immix Biopharma, Inc.
- [ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors](https://immixbio.com/immixbio-ships-tislelizumab-for-patient-dosing-in-its-combination-clinical-trial-with-imx-110-in-advanced-solid-tumors/) - Tislelizumab supplied by BeiGene as part of ImmixBio's Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid TumorsIMX-110 + Tislelizumab clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor
- [Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)](https://immixbio.com/immix-biopharma-in-licenses-nxc-201-bcma-targeted-next-generation-car-t-therapy-demonstrating-high-complete-response-rate-in-heavily-pre-treated-multiple-myeloma-71-complete-responses-and-al-amyloi/) - Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff (Haematologica https://doi.org/10.3324/haematol.2022.281628)AL Amyloidosis - 100% complete responses, 100% organ response rate for NXC-201 in 4 relapsed/refractory patients (Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637)Potential first and only
- [Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial](https://immixbio.com/immix-biopharma-announces-patient-dosing-in-ongoing-phase-1b-2a-imx-110-monotherapy-clinical-trial/) - In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110IMX-110 monotherapy and IMX-110 combination clinical trial with Beigene/Novartis anti-PD-1 tislelizumab enabled by newly manufactured,
- [ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing](https://immixbio.com/immixbio-releases-and-ships-scaled-up-gmp-batches-of-imx-110-for-clinical-trial-patient-dosing/) - LOS ANGELES, CA, Dec. 12, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has completed release testing and shipped Good Manufacturing Practice ("GMP") process manufactured batches of IMX-110 for clinical trial patient dosing. IMX-110 was
- [Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher](https://immixbio.com/immix-biopharma-receives-institutional-review-board-approval-to-enroll-pediatric-patients-in-upcoming-imx-110-clinical-trial-key-requirement-for-u-s-food-and-drug-administration-approval-of-rare-ped/) - Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher ("PRV")While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2020 report on drug development by the Government Accountability Office A
- [Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26](https://immixbio.com/immix-biopharma-to-present-milestones-achieved-to-enable-kick-off-of-2-imx-110-clinical-trials-at-the-2022-thinkequity-conference-on-october-26/) - A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that Chief Executive Officer Ilya Rachman, MD, PhD, and Chief Financial Officer Gabriel Morris will present
- [Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank](https://immixbio.com/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank-2/) - LOS ANGELES, March 10, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank ("SVB") or Silvergate Bank. About Immix Biopharma, Inc.Immix Biopharma, Inc.
- [ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14](https://immixbio.com/immixbio-to-discuss-recent-positive-nxc-201-clinical-data-in-al-amyloidosis-and-multiple-myeloma-at-the-35th-annual-roth-conference-on-march-14-2/) - LOS ANGELES, March 06, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc. ("Nexcella"), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that
- [Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-new-positive-nxc-201-clinical-data-demonstrating-100-complete-responses-in-al-amyloidosis-patients-additional-positive-multiple-myeloma-safety-data/) - LOS ANGELES, March 23, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate - cardiac, renal, liver response - in a total of 8 AL amyloidosis patients (an additional 2
- [Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank](https://immixbio.com/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank/) - LOS ANGELES, March 10, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank ("SVB") or Silvergate Bank. About Immix Biopharma, Inc.Immix Biopharma, Inc.
- [Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-new-positive-nxc-201-clinical-data-demonstrating-100-complete-responses-in-al-amyloidosis-patients-additional-positive-multiple-myeloma-safety-data-2/) - LOS ANGELES, March 23, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate - cardiac, renal, liver response - in a total of 8 AL amyloidosis patients (an additional 2
- [Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program](https://immixbio.com/immix-biopharma-completes-5-million-at-the-market-equity-offering-program/) - Participating institutional investors include Bridgewest GroupLOS ANGELES, June 14, 2023 -- Immix Biopharma, Inc., (Nasdaq:IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering CAR-T cell therapies and tissue specific therapeutics targeting oncology and immuno-dysregulated diseases, today announced that it has completed its previously announced "at-the-market" equity offering program (the "ATM Offering"). "We are delighted
- [Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors](https://immixbio.com/immix-biopharma-subsidiary-nexcella-appoints-henry-mckinnell-jr-former-chairman-ceo-of-pfizer-inc-to-board-of-directors/) - Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive OfficerDr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & Co.)
- [Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site](https://immixbio.com/immix-biopharma-subsidiary-nexcella-announces-commencement-of-nxc-201-engineering-batches-at-its-u-s-car-t-manufacturing-site/) - U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company's existing CAR-T GMP manufacturing process to the United StatesCommencement of U.S. engineering batches follows selection of U.S. GMP manufacturer in February 2023 LOS ANGELES, May 26,
- [Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial](https://immixbio.com/immix-biopharma-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinica/) - 8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS62% (5/8) had NYHA classification III or IV heart failure prior to treatment with NXC-201Best responder duration of response was 16.5
- [Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)](https://immixbio.com/immix-biopharma-announces-late-breaking-nxc-201-clinical-data-abstract-accepted-for-oral-presentation-at-the-26th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy-asgct/) - Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023LOS ANGELES, May 04, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American
- [Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene Anti-PD-1 Antibody Tislelizumab](https://immixbio.com/immix-biopharma-announces-early-positive-imx-110-interim-clinical-trial-data-demonstrating-100-tumor-shrinkage-in-advanced-metastatic-colorectal-cancer-at-the-lowest-dose-of-imx-110-beigene-anti-pd/) - 100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort (two out of two first evaluable patients) in its ongoing phase 1b/2a dose escalation clinical trial IMMINENT-01 We believe results bolster scientific basis for IMX-110 in unlocking
- [Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-positive-58-patient-nxc-201-clinical-data-100-overall-response-rate-in-light-chain-al-amyloidosis-92-overall-response-rate-in-multiple-myeloma-at/) - Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.3 months as of
- [Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-poster-presentation-at-the-european-society-for-blood-and-marrow-transplantation-49th-annual-meeting/) - Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023LOS ANGELES, April 04, 2023 -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected to be
- [Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells/) - LOS ANGELES, March 31, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And
- [Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site](https://immixbio.com/immix-biopharma-subsidiary-nexcella-announces-commencement-of-nxc-201-engineering-batches-at-its-u-s-car-t-manufacturing-site-2/) - U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company's existing CAR-T GMP manufacturing process to the United StatesCommencement of U.S. engineering batches follows selection of U.S. GMP manufacturer in February 2023 LOS ANGELES, May 26,
- [Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial](https://immixbio.com/immix-biopharma-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinic-2/) - 8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS62% (5/8) had NYHA classification III or IV heart failure prior to treatment with NXC-201Best responder duration of response was 16.5
- [Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)](https://immixbio.com/immix-biopharma-announces-late-breaking-nxc-201-clinical-data-abstract-accepted-for-oral-presentation-at-the-26th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy-asgct-2/) - Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023LOS ANGELES, May 04, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American
- [Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells-2/) - LOS ANGELES, March 31, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And
- [Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program](https://immixbio.com/immix-biopharma-completes-5-million-at-the-market-equity-offering-program-2/) - Participating institutional investors include Bridgewest GroupLOS ANGELES, June 14, 2023 -- Immix Biopharma, Inc., (Nasdaq:IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering CAR-T cell therapies and tissue specific therapeutics targeting oncology and immuno-dysregulated diseases, today announced that it has completed its previously announced "at-the-market" equity offering program (the "ATM Offering"). "We are delighted
- [Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors](https://immixbio.com/immix-biopharma-subsidiary-nexcella-appoints-henry-mckinnell-jr-former-chairman-ceo-of-pfizer-inc-to-board-of-directors-2/) - Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive OfficerDr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & Co.)
- [Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene Anti-PD-1 Antibody Tislelizumab](https://immixbio.com/immix-biopharma-announces-early-positive-imx-110-interim-clinical-trial-data-demonstrating-100-tumor-shrinkage-in-advanced-metastatic-colorectal-cancer-at-the-lowest-dose-of-imx-110-beigene-anti-pd-2/) - 100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort (two out of two first evaluable patients) in its ongoing phase 1b/2a dose escalation clinical trial IMMINENT-01 We believe results bolster scientific basis for IMX-110 in unlocking
- [Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-positive-58-patient-nxc-201-clinical-data-100-overall-response-rate-in-light-chain-al-amyloidosis-92-overall-response-rate-in-multiple-myeloma-at-2/) - Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.3 months as of
- [Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting](https://immixbio.com/nexcella-an-immix-biopharma-subsidiary-announces-poster-presentation-at-the-european-society-for-blood-and-marrow-transplantation-49th-annual-meeting-2/) - Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023LOS ANGELES, April 04, 2023 -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected to be
- [Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors](https://immixbio.com/immix-biopharma-subsidiary-nexcella-appoints-mary-sue-coleman-former-johnson-johnson-independent-director-to-board-of-directors/) - Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016Dr. Coleman is President Emerita of the University of Michigan where she was named one of "10 Best College Presidents" by TIME Magazine and served as President of the University of
- [Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors](https://immixbio.com/immix-biopharma-subsidiary-nexcella-appoints-mary-sue-coleman-former-johnson-johnson-independent-director-to-board-of-directors-2/) - Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016Dr. Coleman is President Emerita of the University of Michigan where she was named one of "10 Best College Presidents" by TIME Magazine and served as President of the University of
- [Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing](https://immixbio.com/immix-biopharma-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-patient-dosing/) - NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain (AL) AmyloidosisFavorable tolerability enables expansion into autoimmune indications LOS ANGELES, Nov. 21, 2023 -- Immix Biopharma, Inc. (Nasdaq:IMMX) ("ImmixBio", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company advancing
- [Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients](https://immixbio.com/immix-biopharma-presents-nxc-201-data-at-65th-american-society-of-hematology-ash-annual-meeting-in-9-relapsed-refractory-al-amyloidosis-patients/) - 100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10, 2023 LOS ANGELES, Nov. 06, 2023 -- Immix Biopharma, Inc. (Nasdaq:IMMX) ("ImmixBio", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today
- [Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients](https://immixbio.com/immix-biopharma-presents-nxc-201-data-at-65th-american-society-of-hematology-ash-annual-meeting-in-63-relapsed-refractory-multiple-myeloma-patients/) - 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy98% overall response rate observed in relapsed/refractory multiple myeloma patients without extra-medullary diseaseUpdated results will be communicated at the presentation time December 11, 2023 LOS ANGELES, Nov. 06, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"),
- [Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board](https://immixbio.com/immix-biopharma-subsidiary-nexcella-announces-dr-michaela-liedtke-stanford-medicine-cancer-center-hematology-program-lead-and-co-director-stanford-amyloid-center-joins-scientific-advisory-board/) - Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in CAR-T cell therapy and designing clinical trials in AL Amyloidosis and Multiple Myeloma LOS ANGELES, Oct. 26, 2023 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us"), announced that
- [Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site](https://immixbio.com/immix-biopharma-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site/) - Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing facility in California LOS ANGELES, Oct. 16, 2023 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us") today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen
- [Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting](https://immixbio.com/immix-biopharma-announces-complete-response-in-9th-relapsed-refractory-al-amyloidosis-patient-in-nxc-201-clinical-trial-at-ims-20th-annual-meeting/) - 100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff100% (4/4) overall response rate and 75% (3/4) complete response rate observed in t(11;14) relapsed/refractory AL AmyloidosisBest responder duration of response was 19.2 months with
- [Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma](https://immixbio.com/immix-biopharma-announces-72-patient-nxc-201-clinical-data-at-the-ims-20th-annual-meeting-95-overall-response-rate-in-multiple-myeloma/) - 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off90% overall response rate observed in relapsed/refractory multiple myeloma at the therapeutic dose including patients with, and without prior BCMA-targeted therapyClass-Leading Response Rate in
- [U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis](https://immixbio.com/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-immix-biopharma-nxc-201-as-a-treatment-for-amyloid-light-chain-al-amyloidosis/) - FDA Orphan Drug Designation ("ODD") qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testingWaiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug)The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to
- [Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site](https://immixbio.com/immix-biopharma-subsidiary-nexcella-completes-2nd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site/) - Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.Plan for NXC-201 to expand into earlier lines of therapy, and beyond the 5% of U.S. hospitals that offer CAR-T today LOS ANGELES, Sept. 19, 2023 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company pioneering
- [Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference](https://immixbio.com/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference/) - LOS ANGELES, Sept. 07, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26,
- [Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board](https://immixbio.com/immix-biopharma-announces-dr-suzanne-lentzsch-director-of-the-multiple-myeloma-and-amyloidosis-program-at-the-college-of-physicians-and-surgeons-of-columbia-university-and-at-new-york-presbyterian-h/) - Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.Dr. Lentzsch is an internationally recognized expert in multiple myeloma and AL Amyloidosis; Co-Chairs the National Cancer Institute Myeloma Steering Committee; is an Associate
- [U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma](https://immixbio.com/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-immix-biopharma-nxc-201-as-a-treatment-for-multiple-myeloma/) - FDA Orphan Drug Designation ("ODD") qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testingWaiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug)The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock,
- [Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board](https://immixbio.com/immix-biopharma-announces-dr-heather-landau-memorial-sloan-kettering-cancer-center-amyloidosis-program-director-joins-nexcella-scientific-advisory-board/) - Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought leader in CAR-T cell therapy, bone marrow and solid organ transplantation and novel treatment approaches to plasma cell disorders including AL Amyloidosis and Multiple Myeloma LOS ANGELES, Aug.
- [Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)](https://immixbio.com/immix-biopharma-announces-additional-nxc-201-al-amyloidosis-clinical-data-accepted-for-oral-presentation-at-the-20th-international-myeloma-society-annual-meeting-september-27-30-athens-greece/) - LOS ANGELES, Aug. 16, 2023 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens,
- [Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting](https://immixbio.com/immix-biopharma-subsidiary-nexcella-announces-nxc-201-multiple-myeloma-clinical-data-abstract-accepted-for-presentation-at-the-20th-international-myeloma-society-annual-meeting/) - Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023LOS ANGELES, July 25, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. ("Nexcella", "Company", "We" or "Us"), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming
- [Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial](https://immixbio.com/immix-biopharma-reports-2nd-positive-interim-clinical-trial-data-readout-in-relapsed-refractory-metastatic-colorectal-cancer-in-ongoing-phase-1b-2a-imx-110-imminent-01-clinical-trial/) - Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumabDose Escalation Proceeding: dosing of 2nd
- [Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site](https://immixbio.com/immix-biopharma-subsidiary-nexcella-completes-initial-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site/) - Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.LOS ANGELES, July 10, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. ("Nexcella", "Company", "We" or "Us"), today announced the completion of its initial CAR-T NXC-201 engineering batch at its U.S. manufacturing site. This represents an important step forward
- [Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial](https://immixbio.com/immix-biopharma-subsidiary-nexcella-completes-pre-ind-meeting-with-fda-on-nxc-201-us-clinical-trial/) - LOS ANGELES, June 26, 2023 -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. ("Nexcella", "Company", "We" or "Us"), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, today announced it has completed a Pre-Investigational New Drug ("Pre-IND") meeting with the FDA. The subject of the Pre-IND meeting was planned NXC-201 US manufacturing
- [Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors](https://immixbio.com/immix-biopharma-subsidiary-nexcella-appoints-edward-j-borkowski-former-chief-financial-officer-of-mylan-n-v-to-board-of-directors/) - Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of Mylan N.V. Mr. Borkowski is also the former Chief Financial Officer of CareFusion, which was ultimately acquired by Becton Dickinson for $12.2 billion LOS ANGELES,
- [Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors](https://immixbio.com/immix-biopharma-subsidiary-nexcella-appoints-jeffrey-h-cooper-former-chief-financial-officer-of-biomarin-to-board-of-directors/) - Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin Pharmaceutical Mr. Cooper is a former independent director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9 billion in 2022 and Tobira Therapeutics, acquired by Allergan (now
- [California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)](https://immixbio.com/california-institute-for-regenerative-medicine-awards-funding-for-car-t-nxc-201-u-s-al-amyloidosis-clinical-trial-nexicart-2/) - $8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us", "IMMX") (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Immix Biopharma
- [Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201](https://immixbio.com/immix-biopharma-doses-1st-patient-in-u-s-al-amyloidosis-trial-with-car-t-nxc-201/) - Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us", "IMMX") (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis
- [Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum](https://immixbio.com/immix-biopharma-to-present-at-the-stifel-2024-cell-therapy-forum/) - LOS ANGELES, June 17, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9,
- [Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation](https://immixbio.com/immix-biopharma-announces-positive-nxc-201-relapsed-refractory-al-amyloidosis-clinical-data-in-asgct-2024-late-breaking-oral-presentation/) - 92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond Best responder
- [Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma](https://immixbio.com/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-multiple-myeloma/) - European Orphan Drug Designation ("ODD") qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees LOS ANGELES, April 29, 2024 -- Immix
- [Immix Biopharma on Track to Dose NXC-201 Patients in United States](https://immixbio.com/immix-biopharma-on-track-to-dose-nxc-201-patients-in-united-states/) - Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"),
- [Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)](https://immixbio.com/immix-biopharma-announces-late-breaking-nxc-201-clinical-data-abstract-accepted-for-oral-presentation-at-the-27th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy-asgct/) - Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated
- [Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial](https://immixbio.com/immix-biopharma-announces-major-comprehensive-cancer-center-as-lead-site-for-nxc-201-al-amyloidosis-clinical-trial/) - LOS ANGELES, CA, March 20, 2024 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. "We are
- [Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative](https://immixbio.com/immix-biopharma-announces-be-proactive-in-al-al-amyloidosis-awareness-initiative/) - Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own wordsLOS ANGELES, CA, March 05, 2024 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL
- [Immix Biopharma 12 Month Review Progress Update](https://immixbio.com/immix-biopharma-12-month-review-progress-update/) - LOS ANGELES, Feb. 21, 2024 -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter. "The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease. We successfully
- [Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock](https://immixbio.com/immix-biopharma-announces-closing-of-15-million-public-offering-of-common-stock/) - LOS ANGELES, CA, Feb. 08, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a
- [Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis](https://immixbio.com/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-al-amyloidosis/) - European Orphan Drug Designation ("ODD") qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees U.S. observed prevalence of relapsed/refractory AL Amyloidosis
- [Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock](https://immixbio.com/immix-biopharma-announces-pricing-of-15-million-public-offering-of-common-stock/) - LOS ANGELES, CA, Feb. 05, 2024 -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common
- [Immix Biopharma Announces Proposed Public Offering of Common Stock](https://immixbio.com/immix-biopharma-announces-proposed-public-offering-of-common-stock/) - LOS ANGELES, Feb. 05, 2024 -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the "Company"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are
- [Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products](https://immixbio.com/immix-biopharma-statement-on-january-2024-fda-labeling-change-notification-for-approved-car-t-products/) - LOS ANGELES, CA, Jan. 24, 2024 -- Immix Biopharma, Inc. ("Immix Biopharma", "Company", "We" or "Us", Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products: "We applaud FDA's vigilance. Relapsed/refractory AL Amyloidosis remains an unmet medical need with
- [Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board](https://immixbio.com/immix-biopharma-announces-dr-vaishali-sanchorawala-al-amyloidosis-thought-leader-director-of-the-amyloidosis-center-at-boston-university-and-boston-medical-center-joins-scientific-advisory-board/) - Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of careLOS ANGELES, Jan. 04, 2024 -- Immix Biopharma, Inc. ("Immix Biopharma", "Company", "We" or "Us", Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio
- [Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board](https://immixbio.com/immix-biopharma-announces-dr-marko-radic-autoimmune-car-t-pioneer-and-associate-professor-at-the-university-of-tennessee-health-science-center-joins-scientific-advisory-board/) - Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in autoimmune CAR-T cell therapy, antibody-mediated disorders and designing CAR-T studies LOS ANGELES, Dec. 18, 2023 -- Immix Biopharma, Inc. ("Immix Biopharma", "Company", "We" or "Us"), announced that
- [Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023](https://immixbio.com/immix-biopharma-announces-100-overall-response-rate-n10-23-7-months-best-response-duration-ongoing-for-car-t-nxc-201-in-relapsed-refractory-al-amyloidosis-patients-at-ash-2023/) - 100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023Best responder duration of response was 23.7 months with response ongoing as of December 10, 2023U.S.
- [Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit](https://immixbio.com/immix-biopharma-to-present-at-the-2023-jmp-securities-hematology-and-oncology-summit/) - LOS ANGELES, Nov. 30, 2023 -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit. The JMP Securities Hematology and Oncology Summit Presentation
- [Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis](https://immixbio.com/immix-biopharma-to-host-kol-event-to-discuss-its-bcma-targeted-car-t-cell-therapy-candidate-nxc-201-for-relapsed-refractory-al-amyloidosis/) - Virtual Event to be held on November 29, 2023 at 4:15 p.m. ETLOS ANGELES, Nov. 22, 2023 -- Immix Biopharma, Inc. (Nasdaq:IMMX) ("ImmixBio", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that it will host a virtual KOL event to discuss its BCMA-Targeted CAR-T cell therapy

## Pages

- [Home](https://immixbio.com/) - New Hope for relapsed/refractory AL Amyloidosis ASH Presentation PressRelease Corporate Presentation KOL Event to Discuss ASH 2025 NXC-201 NEXICART-2 Phase 2 Clinical Results Oral Presentation and landscape in relapsed/refractory AL Amyloidosis Hear it From the Media ASCO Post Interview: Shahzad Raza, MD (Cleveland Clinic) Memorial Sloan Kettering: Strong Results for NXC-201 at ASCO Cleveland Clinic:
- [Investors](https://immixbio.com/investors/) - INVEST IN THE FUTURE AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES CELL THERAPY CLINICAL TRAILBLAZER Immix Biopharma is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and select other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2a
- [The Science - Pipeline and Publicatioms](https://immixbio.com/the-science-pipeline-and-publications/) - PIPELINE & PUBLICATIONS Pipeline Only CAR-T in AL Amyloidosis. Lead Program: NXC-201, a sterically-optimized BCMA-targeting CAR-T for AL Amyloidosis and other serious diseases. Indication Relapsed/ Refractory AL Amyloidosis​ Therapy NXC-201 A sterically-optimized chimeric antigen receptor T (CAR-T) cell therapy in development for the treatment of Relapsed/Refractory AL Amyloidosis and autoimmune diseases. An autologous CAR-T therapy
- [About Us - Meet The Team](https://immixbio.com/about-us-meet-the-team/) - MEET THE TEAM TEAM Meet our team of innovators and thinkers at Immix Biopharma, whose dedication and expertise are paving the way for revolutionary treatments in AL Amyloidosis and other serious diseases. Hear their insights and learn about the passion that drives our mission forward. Ilya Rachman, MD PhD Chief Executive Officer UCLA Health, Cedars
- [Landing Page](https://immixbio.com/landing-page/) - Changing the Sentence Forever “Are there any options left for AL Amyloidosis?” Because of Immix, the answer is finally: “Yes.” We’ve found a breakthrough to change that hopeless sentence.Our mission is simple: Create medicines that workwithout destroying the person. Discover the BreakthroughAccess Clinical Results The Stark Reality The Current Paradigm is Failing When AL Amyloidosis Comes
- [Investors - Analyst Coverage](https://immixbio.com/investors-analyst-coverage/) - ANALYST COVERAGE EDISON RESEARCH Soo RomanoffDr Harry ShrivesDr Adam McCarter ROTH MKM Jonathan Aschoffjaschoff@roth.com THINKEQUITY Ashok Kumarak@think-equity.com Track all markets on TradingView LET’S BUILD SOMETHING GREAT TOGETHER Join our newsletter for exclusive insights into groundbreaking medical advancements, the latest in research, and transformative therapies. Stay informed and be part of shaping the future of healthcare.
- [About Us](https://immixbio.com/about-us/) - ABOUT US The Global Leader in Relapsed/Refractory AL Amyloidosis Imagine a world where patients with AL amyloidosis and other serious diseases can access a one-time, transformative treatment right at their doorstep. At ImmixBio, we see a horizon where this is possible. Based on the groundbreaking cell therapy research in the early 2010s of Dr. Carl
- [Patient First](https://immixbio.com/patient-first/) - PATIENT FIRST Do you or a loved one suffer from AL Amyloidosis? Discover if you qualify for our clinical trial and take a proactive step towards potential groundbreaking treatment. Join us in advancing care and contributing to medical research that could change lives. LEARN MORE Voices of Hope: Real Stories from AL Amyloidosis Warriors Discover
- [News](https://immixbio.com/news/) - NEWS
- [Contact Us](https://immixbio.com/contact-us/) - Join our newsletter for exclusive insights into groundbreaking medical advancements, the latest in research, and transformative therapies. Stay informed and be part of shaping the future of healthcare. Sign up today!
- [The Science](https://immixbio.com/the-science/) - THE SCIENCE IMMIXBIO N-GENIUS STERICALLY-OPTIMIZED CELL THERAPY PLATFORM Our N-GENIUS platform, with EXPAND technology, has produced our pioneering lead candidate, CAR-T NXC-201, which has demonstrated an enhanced tolerability profile with the potential to reduce hospitalizations. https://vimeo.com/995423052?share=copy HEAR FROM CLINICIANS https://www.youtube.com/watch?v=rLdoxcDr0jAhttps://www.youtube.com/watch?v=ByWLQRDDol0https://www.youtube.com/watch?v=rPPoYF7Yp58 WHAT IS NXC-201 CAR-T THERAPY? Each of our bodies has an immune system that recognizes
- [Privacy Policy](https://immixbio.com/privacy-policy-2/) - Privacy Policy Last updated: July 03, 2024 This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service and tells You about Your privacy rights and how the law protects You. We use Your Personal data to provide and improve the Service. By using
- [The Science - Solid Tumors](https://immixbio.com/the-science-solid-tumors/) - SOLID TUMORS SMARxT Tissue-Specific™ Platform The application of the SMARxT Tissue-Specific Platform in oncology is TME Normalization Technology, and in immuno-dysregulated diseases is Immune Normalization Technology. https://player.vimeo.com/video/589870791?dnt=1&app_id=122963 SMARXT TISSUE-SPECIFIC™ PLATFORM System-Tissue Biology Model Development Interplay of cellular elements define and drive disease states. Based on transcriptional and epigenetic factors operating in key cell types, we
- [Investors - Stock Information](https://immixbio.com/investors-stock-information/) - STOCK INFO STOCK PRICE STOCK CHART HISTORICAL DATA LET’S BUILD SOMETHING GREAT TOGETHER Join our newsletter for exclusive insights into groundbreaking medical advancements, the latest in research, and transformative therapies. Stay informed and be part of shaping the future of healthcare. Sign up today! ADD FORM HERE
- [Investors - SEC Filings](https://immixbio.com/investors-sec-filings/) - SEC FILINGS Track all markets on TradingView LET’S BUILD SOMETHING GREAT TOGETHER Join our newsletter for exclusive insights into groundbreaking medical advancements, the latest in research, and transformative therapies. Stay informed and be part of shaping the future of healthcare. Sign up today! ADD FORM HERE
- [Investors - Governance](https://immixbio.com/investors-governance/) - GOVERNANCE GOVERNANCE DOCUMENTS Code of Business Conduct and Ethics CHARTERS Corporate Governance and Nominating Committee Charter Audit Committee Charter Compensation Committee Charter Track all markets on TradingView LET’S BUILD SOMETHING GREAT TOGETHER Join our newsletter for exclusive insights into groundbreaking medical advancements, the latest in research, and transformative therapies. Stay informed and be part of
- [Investors - FAQ](https://immixbio.com/investors-faq/) - INVESTOR FAQS Where is Immix Biopharama’s corporate headquarters? Our corporate headquarters are in Los Angeles, California. Where is Immix Biopharma incorporated? Immix Biopharma is incorporated under the laws of the State of Delaware. What is Immix Biopharma’s fiscal year? Our fiscal year is January 1st to December 31st. How is Immix Biopharma’s stock traded? We

## My Templates

- [Elementor Footer #1015](https://immixbio.com/?elementor_library=elementor-footer-1015) - 11400 West Olympic Blvd, Suite 200Los Angeles, CA 90064T: (310) 651-8041© Immix Biopharma, Inc. Facebook Linkedin
- [Elementor Header #15](https://immixbio.com/?elementor_library=elementor-header-15) - The Global Leader in Relapsed/Refractory AL Amyloidosis
- [Default Kit](https://immixbio.com/?elementor_library=default-kit)
- [Post-Template](https://immixbio.com/?elementor_library=post-template-2)
- [Elementor #1761](https://immixbio.com/?elementor_library=elementor-1761) - COMING SOON…
- [Post Template](https://immixbio.com/?elementor_library=post-template) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [Elementor Loop Item #1236](https://immixbio.com/?elementor_library=elementor-loop-item)
- [IMMX-Page-Template](https://immixbio.com/?elementor_library=immx-page-template) - Autoimmune CAR-T Clinical Trailblazer SOLVING AUTOIMMUNITY IMMIX BIOPHARMA Prioritizing Patient wellbeing Prioritizing patient well-being with innovative treatments that simplify and enhance the recovery process. More Voices of Hope: Real Stories from AL Amyloidosis Warriors Discover the transformative journeys of individuals who have bravely navigated their treatment with our groundbreaking therapy. Hear firsthand how their lives

## Categories

- [Press Releases](https://immixbio.com/category/press-releases/)